Tetraphase Pharmaceuticals Presents Preclinical Data on TP-2846, a Novel Drug Candidate for Acute Myeloid Leukemia
April 03 2019 - 8:00AM
Business Wire
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a
biopharmaceutical company focused on developing and commercializing
novel tetracyclines to treat serious and life-threatening
conditions, today announced data from its preclinical program for
TP-2846, the Company’s new pipeline candidate for acute myeloid
leukemia (AML) discovered using Tetraphase’s proprietary total
synthesis platform. The data were presented at the 2019 American
Association for Cancer Research (AACR) Annual Meeting, held March
29-April 3 at the Georgia World Congress Center in Atlanta. The
posters showed results from preclinical in vitro and in vivo
studies demonstrating the activity, potency and unique mechanism of
action (MOA) of TP-2846.
“Preclinical testing has characterized TP-2846 as a novel,
potent, synthetic tetracycline with activity across multiple in
vitro and in vivo cancer models,” said Guy Macdonald, President and
Chief Executive Officer of Tetraphase. “We are very encouraged by
these early data, which suggest that TP-2846 holds the potential to
benefit AML patients regardless of their mutation status. Further,
these data show that because of its unique MOA, TP-2846 may have
antileukemic activity in patients whose cancer has progressed while
on different treatment regimens.”
“TP-2846 has a new MOA that has never before been fully explored
clinically as a viable approach to treating AML,” said Jacques
Dumas, Chief Scientific Officer of Tetraphase. “Our preclinical
data demonstrated high potency across multiple AML cell lines,
along with in vivo tumor responses at well-tolerated doses. These
early data are very encouraging and support the continued
preclinical evaluation of TP-2846 as a potential new antileukemia
agent.”
TP-2846 binds to the mitochondrial ribosome, inhibiting protein
translation and inducing apoptosis. Mechanistic assays demonstrated
changes in protein and gene expression – all consistent with
disruption of mitochondrial translation.
TP-2846 showed antiproliferative activity against cultured AML
cell lines in vitro, as well as bone marrow samples derived from
AML patients in ex vivo assays. The data available to date also
suggest that TP-2846’s activity is independent of p53 status.
Because of its novel MOA, TP-2846 maintained antiproliferative
activity in cell lines that are resistant to anthracyclines,
cytarabine and venetoclax, which are currently approved treatments
for AML.
In vivo efficacy studies were also performed, comparing TP-2846
to cytarabine and tigecycline, a tetracycline antibacterial, in two
AML mouse xenograft models. In these studies, TP-2846 demonstrated
potent, dose-dependent in vivo efficacy, including greater than 50
percent tumor shrinkage in 19 out of 20 animals treated with
TP-2846, while none in the comparator treatment groups achieved a
tumor response in the same studies. TP-2846 was well tolerated in
both models.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company
using its proprietary chemistry technology to create novel
tetracyclines for serious and life-threatening conditions,
including bacterial infections caused by many of the
multidrug-resistant bacteria highlighted as urgent public health
threats by the World Health Organization and the Centers for
Disease Control and Prevention. The Company has created more than
3,000 novel tetracycline compounds using its proprietary technology
platform. Tetraphase's lead product, XERAVATM (eravacycline), is
approved for the treatment of complicated intra-abdominal
infections by the U.S. Food and Drug Administration and the
European Medicines Agency. The Company’s pipeline includes TP-271
and TP-6076, which are in Phase 1 clinical trials, and TP-2846,
which is in preclinical testing for acute myeloid leukemia. Please
visit www.tphase.com for more company information.
Forward-Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
including our key milestones for 2019 and our anticipated cash
runway, and other statements containing the words "anticipates,"
"believes," "expects," "plans," "will" and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
whether preclinical data is indicative of expected clinical data;
our cash resources and the expected revenue will be sufficient to
fund our operations in the future; our product candidates, such as
TP2846, will succeed in clinical trials; even if such clinical
trials are successful, whether we may ever achieve regulatory
approval of such product candidates and other clinical, regulatory
and commercial risk factors discussed in the "Risk Factors" section
of our annual report on Form 10-K for the period ended December 31,
2018, filed with the Securities and Exchange Commission on March
15, 2019. In addition, the forward-looking statements included in
this press release represent our views as of April 3, 2019. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005264/en/
Jennifer Vierajviera@tphase.com617-600-7040
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From May 2023 to May 2024